載入...
Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
BACKGROUND: At least 50% of triple negative breast cancer (TNBC) overexpress the epidermal growth factor receptor, EGFR, which paved the way for clinical trials investigating its blockade. Outcomes remained dismal stemming from mechanisms of resistance particularly the nuclear cycling of EGFR, which...
Na minha lista:
| 發表在: | Breast Cancer Res |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7160960/ https://ncbi.nlm.nih.gov/pubmed/32295603 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01270-1 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|